KRRO - NASDAQ
Korro Bio, Inc.
$11.08
+2.1%Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
At a Glance
Live SnapshotKorro Bio, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Korro Bio, Inc. Cash Flow Statement
KRRO • NASDAQ
| Korro Bio, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
-117.3M | -83.6M | -81.2M | -58M | -22M | -10.2M | -18.7M | -19.2M | -20.2M | |
3.8M | 3.6M | 3.6M | 2.5M | 1.6M | 1.6M | 813K | 654K | 531K | |
0.0 | 0.0 | 0.0 | -145K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
7.7M | 4.5M | 2.4M | 1.1M | 807K | 0.0 | 0.0 | 0.0 | 0.0 | |
31.7M | 1.9M | 3.6M | 1.5M | -13.4M | -6.3M | 3.5M | 2M | 5.9M | |
(0.0) | (141K) | (27K) | (11K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-4.4M | 13.6M | 4.3M | -633K | 904K | -30.2M | 48.6M | 819K | 276K | |
-78.6M | -60.1M | -67.3M | -53.6M | -32.1M | -45.2M | 34.2M | -17M | -14.6M | |
INVESTING ACTIVITIES | |||||||||
-518K | -17.9M | -7.8M | -5.2M | -4.4M | -6.7M | -1.1M | -436K | -1.9M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (3.8M) | (0.0) | |
-26.2M | -146.3M | (0.0) | -37.2M | -35.1M | -26.3M | -282.6M | (0.0) | (0.0) | |
70.7M | 40.9M | 19M | 53.5M | 0.0 | 43.4M | 265.4M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 13K | 0.0 | 0.0 | 0.0 | 0.0 | |
(44M) | -123.3M | (11.2M) | (11.1M) | -39.5M | (10.4M) | -18.3M | (3.3M) | -1.9M | |
FINANCING ACTIVITIES | |||||||||
685K | 67.4M | 117.3M | 62K | 0.0 | 41.7M | 142M | 32.9M | 28M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 15M | 0.0 | 5M | 0.0 | |
0.0 | 2M | 25.1M | -44K | -2K | 0.0 | 0.0 | 0.0 | 0.0 | |
685K | 69.4M | 187.8M | 18K | 115.9M | 56.7M | 142M | 37.9M | 28M | |
CASH FLOW SUMMARY | |||||||||
64K | -4K | 0.0 | 0.0 | 0.0 | -1.7M | 0.0 | 0.0 | 0.0 | |
-33.8M | -114.1M | 131.6M | -42.6M | 44.4M | 20.2M | 158M | 24.3M | 11.5M | |
59M | 173.1M | 41.5M | 84M | 39.7M | 200.2M | 42.2M | 17.9M | 6.4M | |
25.2M | 59M | 173.1M | 41.5M | 84M | 220.3M | 200.2M | 42.2M | 17.9M | |
-79.1M | -78M | -75.1M | -58.9M | -36.5M | -51.9M | 33.2M | -17.5M | -16.5M |
SEC Filings
KRRO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 19, 2026 | May 19, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 16, 2026 | June 10, 2026 | 2026 | |
S-3 S-3 N/A | March 13, 2026 | March 13, 2026 | ||
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 27, 2026 | January 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 15, 2026 | January 15, 2026 | 2026 |
Related Guides
Continue your KRRO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.